p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Jurnal Respirasi (JR)
Putri Chairani Eyanoer
Department of Community and Preventive Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

ROS1 Expression and Histopathological Grading in Non-Small Cell Lung Cancer Patients at Tertiary Hospitals in Medan, Indonesia Nurul Syuhada Parinduri; Noni Novisari Soeroso; Desfrina Kasuma; Putri Chairani Eyanoer; Darren Wan-Teck Lim
Jurnal Respirasi Vol. 12 No. 2 (2026): May 2026
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v12-I.2.2026.126-131

Abstract

Introduction: Lung cancer remains the leading cause of cancer-related mortality worldwide, with most cases classified as non-small cell lung cancer (NSCLC). Genetic alterations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), Kirsten rat sarcoma viral oncogene homolog (KRAS), mesenchymal-epithelial transition (MET), and c-ros oncogene 1 (ROS1) play important roles in guiding targeted therapy strategies. This study aimed to evaluate ROS1 expression in patients with histopathologically confirmed NSCLC and to determine its association with histopathological grading and tumor subtype. Methods: This analytical observational study employed a cross-sectional design using 120 paraffin-embedded tissue samples obtained from NSCLC patients at several hospitals in Medan, Indonesia, between March 2024 and March 2025. Associations were analyzed using the Chi-square test, with p<0.05 considered statistically significant. Results: Adenocarcinoma was the predominant histopathological subtype, accounting for 75% of cases. Positive ROS1 expression was identified in 64.2% of patients. A significant association was observed between ROS1 expression and histopathological grading (p=0.048), whereas no significant association was found between ROS1 expression and histopathological subtype (p=0.742). Receiver operating characteristic (ROC) analysis demonstrated limited diagnostic performance of ROS1 expression, with an area under the curve (AUC) value of 0.451. Conclusion: The ROS1 expression was significantly associated with histopathological grading but showed no correlation with histopathological subtype in NSCLC patients. The ROS1 immunohistochemistry may serve as a practical screening tool in NSCLC, although its diagnostic performance remains limited.
Platinum-Based Chemotherapy Regimens and the Incidence of Chemotherapy Toxicity in Patients with Lung Cancer in Medan, Indonesia Faidul Hidayati Siska Ginting; Noni Novisari Soeroso; Setia Putra Tarigan; Putri Chairani Eyanoer; David Chi Leung Lam
Jurnal Respirasi Vol. 12 No. 3 (2026): September 2026
Publisher : Faculty of Medicine Universitas Airlangga

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.20473/jr.v12-I.3.2026.250-257

Abstract

Introduction: Platinum-based chemotherapy remains the standard first-line therapy for advanced lung cancer; however, its administration is frequently associated with various hematologic and non-hematologic toxicities that may affect patient outcomes and quality of life. Understanding the toxicity profile of platinum-based regimens is essential for optimizing supportive care and treatment monitoring. Objective: This study aimed to analyze the association between platinum-based chemotherapy regimens and the incidence of chemotherapy-related toxicities in lung cancer patients in Medan. Methods: A retrospective study was conducted using medical records of lung cancer patients treated at Prof. dr. Chairuddin P. Lubis Universitas Sumatera Utara Hospital and Adam Malik Hospital from January 2023 to June 2025. Sequential sampling was applied to patients who had received at least two cycles of platinum-based chemotherapy. Hematologic and non-hematologic toxicities were assessed and graded according to the highest toxicity level observed during treatment. Data were analyzed using univariate analysis and Chi-square tests with SPSS version 29. Results: A total of 134 patients were included, predominantly male (85.07%) and aged over 60 years (48.51%). Adenocarcinoma was the most common subtype (57.46%), while carboplatin-based regimens were more frequently administered (75.37%). The most common hematologic toxicity was anemia (76.12%), whereas myalgia (95.52%), pulmonary complications (87.31%), nausea/vomiting (85.82%), and alopecia (75.37%) were the most frequent non-hematologic toxicities. Significant associations were identified between platinum-based chemotherapy regimens and the occurrence of diarrhea (p=0.011) and oral mucositis (p=0.008). Conclusion: Platinum-based chemotherapy in lung cancer patients is associated with substantial hematologic and non-hematologic toxicities, particularly myalgia and pulmonary complications. Carboplatin regimens were more commonly used and generally showed a milder toxicity profile compared with cisplatin. Early monitoring and regimen-specific supportive management are recommended to reduce chemotherapy-related complications.